Vicki Moore, PhD

Contributing Writer https://www.cancertherapyadvisor.com

Vicki Moore, PhD, is a freelance medical writer for Hematology Advisor. Vicki received her PhD in biology from Arizona State University, where her research emphasized molecular biology, biochemistry, and metabolic engineering. She also has experience with predictive analytics and is intrigued by its applications to medicine. Vicki has been a medical writer, focusing on areas of hematology and oncology, among other specialties, since late 2017. You can find her on Linkedin at linkedin.com/in/vicki-moore-93950913

All articles by Vicki Moore, PhD

SGO 2023

Pembrolizumab Improves PFS in Advanced, Recurrent Endometrial Cancer

Vicki Moore, PhD

March 28, 2023

Adding pembrolizumab to chemotherapy improves progression-free survival in advanced or recurrent endometrial cancer, a phase 3 trial suggests.

SGO 2023

No Difference Between Chemoradiotherapy and Chemo Alone in Endometrial Cancer

Vicki Moore, PhD

March 27, 2023

Chemoradiotherapy does not improve overall survival, compared with chemotherapy alone, in patients with locally advanced endometrial cancer, a phase 3 trial suggests.

SGO 2023

54 Million US Women May Lack Access to a Gynecologic Oncologist

Vicki Moore, PhD

March 27, 2023

The number of gynecologic oncologists in the US has grown in recent years, but many patients still lack access to a gynecologic oncologist.

Gastrointestinal Cancers

Esophageal, Gastric Cancer Risks Reduced With Bariatric Surgery for Obesity

Vicki Moore, PhD

February 1, 2023

The use of bariatric surgery in patients with severe obesity is associated with a reduced incidence of esophageal and gastric cancers.

Hematologic Cancers

Comorbidity Burden Predicts Survival in Acute Promyelocytic Leukemia

Vicki Moore, PhD

February 1, 2023

Comorbidity burden is an independent predictor of survival in older patients with acute promyelocytic leukemia.

ASCO GI 2023

Nonsurgical Approach Deemed Feasible for Patients With Early Rectal Cancer

Vicki Moore, PhD

January 25, 2023

A nonsurgical treatment strategy employing chemoradiotherapy is feasible for patients with early rectal cancer, a phase 3 trial suggests.

ASCO GI 2023

Adding Nab-Paclitaxel to Standard Care Does Not Improve Outcomes in Biliary Tract Cancers

Vicki Moore, PhD

January 24, 2023

Adding nab-paclitaxel to gemcitabine and cisplatin does not improve outcomes in newly diagnosed, advanced biliary tract cancers, a phase 3 trial suggests.

Pharmacist giving a medicine bottle to patient

ASCO GI 2023

Trifluridine Plus Tipiracil and Bevacizumab Deemed New Standard Care for Refractory Metastatic Colorectal Cancer

Vicki Moore, PhD

January 23, 2023

Adding bevacizumab to treatment with trifluridine and tipiracil improved outcomes in patients with refractory metastatic colorectal cancer in the phase 3 SUNLIGHT trial.